Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5508066 | Biochimica et Biophysica Acta (BBA) - General Subjects | 2017 | 51 Pages |
Abstract
Human trials have indicated that AS1411 is safe and can induce durable remissions in a few patients, but new strategies are needed to maximize its clinical impact. A better understanding of the mechanisms by which AS1411 targets and kills cancer cells may hasten the development of promising technologies using AS1411-linked nanoparticles or conjugates for cancer-targeted therapy and imaging. This article is part of a Special Issue entitled "G-quadruplex" Guest Editor: Dr. Concetta Giancola and Dr. Daniela Montesarchio.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Paula J. Bates, Elsa M. Reyes-Reyes, Mohammad T. Malik, Emily M. Murphy, Martin G. O'Toole, John O. Trent,